INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 342 filers reported holding INTELLIA THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.72 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,629,832 | -18.1% | 146,421 | +5.7% | 0.00% | -20.0% |
| Q2 2023 | $5,650,110 | +44.6% | 138,551 | +32.2% | 0.01% | +25.0% |
| Q1 2023 | $3,906,530 | +3.3% | 104,817 | -3.3% | 0.00% | 0.0% |
| Q4 2022 | $3,780,331 | -51.8% | 108,350 | -22.4% | 0.00% | -50.0% |
| Q3 2022 | $7,835,000 | +16.3% | 139,675 | +7.5% | 0.01% | +14.3% |
| Q2 2022 | $6,736,000 | -16.4% | 129,877 | +17.3% | 0.01% | 0.0% |
| Q1 2022 | $8,062,000 | -38.3% | 110,709 | -0.0% | 0.01% | -30.0% |
| Q4 2021 | $13,065,000 | -7.4% | 110,721 | +4.6% | 0.01% | -16.7% |
| Q3 2021 | $14,115,000 | -6.3% | 105,825 | +14.0% | 0.01% | -7.7% |
| Q2 2021 | $15,059,000 | +66.2% | 92,827 | -17.6% | 0.01% | +44.4% |
| Q1 2021 | $9,062,000 | +106.9% | 112,681 | +40.4% | 0.01% | +80.0% |
| Q4 2020 | $4,379,000 | +251.2% | 80,252 | +28.6% | 0.01% | +400.0% |
| Q3 2020 | $1,247,000 | +5.9% | 62,420 | +11.4% | 0.00% | 0.0% |
| Q2 2020 | $1,178,000 | +58.3% | 56,035 | -7.9% | 0.00% | 0.0% |
| Q1 2020 | $744,000 | -13.9% | 60,812 | +3.2% | 0.00% | 0.0% |
| Q4 2019 | $864,000 | +8.5% | 58,929 | -1.2% | 0.00% | 0.0% |
| Q3 2019 | $796,000 | -18.4% | 59,624 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $976,000 | +5.9% | 59,624 | +10.5% | 0.00% | 0.0% |
| Q1 2019 | $922,000 | +45.7% | 53,959 | +16.3% | 0.00% | 0.0% |
| Q4 2018 | $633,000 | -69.9% | 46,409 | -36.8% | 0.00% | -50.0% |
| Q3 2018 | $2,100,000 | +18.1% | 73,390 | +12.9% | 0.00% | 0.0% |
| Q2 2018 | $1,778,000 | +27.4% | 64,985 | -1.8% | 0.00% | 0.0% |
| Q1 2018 | $1,396,000 | +10.9% | 66,205 | +1.1% | 0.00% | +100.0% |
| Q4 2017 | $1,259,000 | -16.8% | 65,480 | +7.5% | 0.00% | -50.0% |
| Q3 2017 | $1,514,000 | +91.2% | 60,915 | +23.0% | 0.00% | +100.0% |
| Q2 2017 | $792,000 | +30.5% | 49,517 | +14.9% | 0.00% | 0.0% |
| Q1 2017 | $607,000 | +1.2% | 43,086 | -5.8% | 0.00% | 0.0% |
| Q4 2016 | $600,000 | -55.1% | 45,736 | -41.7% | 0.00% | -50.0% |
| Q3 2016 | $1,336,000 | -19.2% | 78,486 | +1.3% | 0.00% | 0.0% |
| Q2 2016 | $1,654,000 | – | 77,486 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 752,024 | $100,884,000 | 18.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 420,859 | $56,458,000 | 4.40% |
| Discovery Value Fund | 922,411 | $123,741,000 | 3.63% |
| MPM BioImpact LLC | 162,620 | $21,815,000 | 3.38% |
| Ally Bridge Group (NY) LLC | 65,000 | $8,720,000 | 2.56% |
| ARK Investment Management | 6,743,556 | $904,648,000 | 2.17% |
| Integral Health Asset Management, LLC | 50,000 | $6,708,000 | 1.93% |
| Yorktown Management & Research Co Inc | 18,300 | $2,455,000 | 1.85% |
| Interchange Capital Partners, LLC | 8,191 | $1,098,000 | 1.84% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 111,440 | $14,950,000 | 1.76% |